Processa Pharmaceuticals Inc
$ 0.27
1.57%
04 Dec - close price
- Market Cap 15,361,900 USD
- Current Price $ 0.27
- High / Low $ 0.29 / 0.26
- Stock P/E N/A
- Book Value 0.11
- EPS -1.15
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -1.30 %
- ROE -2.71 %
- 52 Week High 1.50
- 52 Week Low 0.15
About
Processa Pharmaceuticals, Inc. (PCSA) is a clinical-stage biopharmaceutical company based in Hanover, Maryland, specializing in the development of innovative therapies for unmet medical needs. With a robust portfolio of proprietary drug candidates, the firm is actively advancing through rigorous clinical trials to address significant health challenges, particularly in under-served therapeutic areas. By prioritizing patient outcomes and striving to enhance quality of life, Processa Pharmaceuticals positions itself as a compelling investment opportunity within the dynamic and rapidly evolving healthcare landscape.
Analyst Target Price
$1.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-11 | 2025-05-08 | 2025-03-27 | 2024-10-30 | 2024-08-13 | 2024-05-10 | 2024-03-29 | 2023-11-13 | 2023-08-10 | 2023-05-15 | 2023-03-30 |
| Reported EPS | -0.07 | -0.25 | -0.3 | -0.74 | -1.03 | -1.01 | -1.11 | -1.7 | -0.08 | -0.097 | -0.18 | -0.36 |
| Estimated EPS | -0.45 | -0.23 | -1.18 | -0.92 | -1 | -0.98 | -1.18 | -1.6 | -0.1 | -0.23 | -0.28 | -0.32 |
| Surprise | 0.38 | -0.02 | 0.88 | 0.18 | -0.03 | -0.03 | 0.07 | -0.1 | 0.02 | 0.133 | 0.1 | -0.04 |
| Surprise Percentage | 84.4444% | -8.6957% | 74.5763% | 19.5652% | -3% | -3.0612% | 5.9322% | -6.25% | 20% | 57.8261% | 35.7143% | -12.5% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PCSA
2024-07-30 12:00:00
Processa Pharmaceuticals announced that the FDA has cleared its Investigational New Drug (IND) application for Next Generation Capecitabine (NGC-Cap) for a Phase 2 clinical trial in advanced or metastatic breast cancer. The trial is expected to begin enrollment this quarter, with initial data anticipated in mid-2025. NGC-Cap aims to provide a more effective chemotherapy with improved safety compared to existing capecitabine monotherapy.
2024-01-18 18:58:00
Processa Pharmaceuticals (PCSA) shares dropped by 23% after the company announced a 1-for-20 reverse stock split. This action is intended to help the company meet Nasdaq's minimum bid price requirement. The reverse split will reduce outstanding shares significantly and take effect on January 22.
2024-01-18 07:45:00
Processa Pharmaceuticals, Inc. announced a 1-for-20 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement. The split will take effect on January 22, 2024, reducing the outstanding shares from approximately 24.6 million to 1.2 million. Stockholders will not receive fractional shares, as holdings will be rounded up to the nearest whole number.
2021-04-11 20:57:26
This article provides a detailed financial overview of Processa Pharmaceuticals, Inc. (PCSA) listed on NASDAQ. It includes stock performance over various periods, key financial stats such as market capitalization, net income, and revenue, as well as information on upcoming earnings, analyst ratings, and company background. The article also features frequently asked questions about PCSA stock performance and investment considerations.
2021-04-02 20:57:26
This article provides a roundup of recent tech deals in the Baltimore area, highlighting Sonatype's acquisition of a startup and various local funding rounds. It also mentions recent hirings and other significant happenings within the regional tech scene.
2018-06-01 12:00:00
Processa Pharmaceuticals has successfully raised $6.88 million through a series of private placements. This funding, comprising an ongoing private placement, a dedicated clinical trial funding, and a mandatory conversion of senior notes, will primarily support the research and development of its lead product candidate, PCS-499, and general corporate purposes. The company is developing products to improve survival and quality of life for patients with high unmet medical needs.
